Changes in Meningococcal Strains in the Era of a Serogroup C Vaccination Campaign: Trends and Evolution in Belgium during the Period 1997-2012

PLoS One. 2015 Oct 1;10(10):e0139615. doi: 10.1371/journal.pone.0139615. eCollection 2015.

Abstract

Background: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitides and septicaemia. This study shows the results of the laboratory-based surveillance of IMD in Belgium over the period 1997-2012.

Methods: The results are based on microbiological and molecular laboratory surveillance of 2997 clinical isolates of N. meningitides received by the Belgian Meningococcal Reference Centre (BMRC) over the period 1997-2012.

Results: Serogroup B has always been a major cause of meningococcal disease in Belgium, with P3.4 as most frequent serotype till 2008, while an increase in non-serotypable strains has been observed in the last few years. Clonal complexes cc-41/44 and cc-269 are most frequently observed in serogroup B strains. In the late nineties, the incidence of serogroup C disease increased considerably and peaked in 2001, mainly associated with phenotypes C:2a:P1.5,2, C:2a:P1.5 and C:2a:P1.2 (ST-11/ET-37 clonal complex). The introduction of the meningococcal C conjugate vaccine has been followed by an 88% significant decrease in serogroup C disease from 2001 to 2004 nationally, yet sharper in Flanders (92%) compared to Wallonia (77%). Since 2008 a difference in incidence of serogroup C was observed in Flanders (0-0.1/100,000) versus Wallonia (0.1-0.3/100,000).

Conclusion: This study showed the change in epidemiology and strain population over a 16 years period spanning an exhaustive vaccination campaign and highlights the influence of regional vaccination policies with different cohorts sizes on short and long-term IMD incidences.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Belgium / epidemiology
  • Biological Evolution*
  • Child
  • Child, Preschool
  • DNA, Bacterial / genetics
  • Female
  • Humans
  • Infant
  • Male
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / microbiology
  • Meningococcal Infections / mortality
  • Meningococcal Infections / prevention & control
  • Meningococcal Vaccines / therapeutic use*
  • Multilocus Sequence Typing
  • Neisseria meningitidis, Serogroup C / classification*
  • Neisseria meningitidis, Serogroup C / genetics*
  • Neisseria meningitidis, Serogroup C / isolation & purification
  • Phenotype
  • Prognosis
  • Serogroup
  • Survival Rate
  • Time Factors
  • Vaccination / mortality*
  • Young Adult

Substances

  • DNA, Bacterial
  • Meningococcal Vaccines
  • serogroup C meningococcal conjugate vaccine